Skip to main content
. Author manuscript; available in PMC: 2022 Aug 10.
Published in final edited form as: Int J Pharm. 2021 Jul 1;605:120844. doi: 10.1016/j.ijpharm.2021.120844

Figure 8.

Figure 8.

A) Plasma concentration of DTG for mice (n=5 per timepoint) implanted with DTG PSIs (278 mg/kg; 10 mg PSI tablet) or with S-DTG/RPV PSIs (278 mg/kg DTG, 296 mg/kg RPV; 20 mg PSI tablet) collected at 24h, 3d, 7d, 14d, 30d, 60d and 90d post implantation. Error bars represent standard deviation of n=5 samples. B) Plasma concentration of DTG plotted for individual mice (n=5 per group) implanted with DTG PSIs (278 mg/kg; 10 mg PSI tablet) or with S-DTG/RPV PSIs (278 mg/kg DTG, 296 mg/kg RPV; 20 mg PSI tablets) collected at 120d, 150d and180d post implantation. C) Plasma concentration of RPV for mice (n=5 per timepoint) implanted with RPV PSIs (296 mg/kg; 10 mg PSI tablet) or with S-DTG/RPV PSIs (278 mg/kg DTG, 296 mg/kg RPV; 20 mg PSI tablets) collected at 24h, 3d, 7d, 14d, 30d, 60d and 90d post implantation. D) Plasma concentration of RPV plotted for individual mouse (n=5 per group) implanted with RPV PSIs (296 mg/kg; 10 mg PSI tablet) or with S-DTG/RPV PSIs (278 mg/kg DTG, 296 mg/kg RPV; 20 mg PSI tablet) collected at 120d, 150d and180d post implantation.